vs

Side-by-side financial comparison of CTO Realty Growth, Inc. (CTO) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

CTO Realty Growth, Inc. is the larger business by last-quarter revenue ($41.2M vs $38.3M, roughly 1.1× ImmunityBio, Inc.). CTO Realty Growth, Inc. runs the higher net margin — 15.1% vs -161.8%, a 176.9% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 15.0%).

Keller Williams Realty is an American technology and international real estate franchise with headquarters in Austin, Texas. It is the largest real estate franchise in the United States by sales volume as of 2022.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

CTO vs IBRX — Head-to-Head

Bigger by revenue
CTO
CTO
1.1× larger
CTO
$41.2M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+392.0% gap
IBRX
407.0%
15.0%
CTO
Higher net margin
CTO
CTO
176.9% more per $
CTO
15.1%
-161.8%
IBRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CTO
CTO
IBRX
IBRX
Revenue
$41.2M
$38.3M
Net Profit
$6.2M
$-61.9M
Gross Margin
99.0%
Operating Margin
175.0%
-169.0%
Net Margin
15.1%
-161.8%
Revenue YoY
15.0%
407.0%
Net Profit YoY
174.4%
-4.7%
EPS (diluted)
$0.13
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTO
CTO
IBRX
IBRX
Q1 26
$41.2M
Q4 25
$38.3M
$38.3M
Q3 25
$37.8M
$32.1M
Q2 25
$37.6M
$26.4M
Q1 25
$35.8M
$16.5M
Q4 24
$35.7M
$7.6M
Q3 24
$31.8M
$6.1M
Q2 24
$28.8M
Net Profit
CTO
CTO
IBRX
IBRX
Q1 26
$6.2M
Q4 25
$28.3M
$-61.9M
Q3 25
$2.9M
$-67.3M
Q2 25
$-23.4M
$-92.6M
Q1 25
$2.3M
$-129.6M
Q4 24
$-15.2M
$-59.2M
Q3 24
$6.2M
$-85.7M
Q2 24
$1.2M
Gross Margin
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
75.0%
99.0%
Q3 25
75.4%
99.4%
Q2 25
73.0%
99.5%
Q1 25
75.2%
99.6%
Q4 24
74.4%
Q3 24
74.4%
Q2 24
71.1%
Operating Margin
CTO
CTO
IBRX
IBRX
Q1 26
175.0%
Q4 25
75.1%
-169.0%
Q3 25
26.6%
-173.5%
Q2 25
-33.7%
-269.8%
Q1 25
22.0%
-390.1%
Q4 24
-20.4%
-919.0%
Q3 24
15.6%
-1314.3%
Q2 24
18.8%
Net Margin
CTO
CTO
IBRX
IBRX
Q1 26
15.1%
Q4 25
73.9%
-161.8%
Q3 25
7.7%
-209.8%
Q2 25
-62.2%
-350.3%
Q1 25
6.3%
-784.9%
Q4 24
-42.6%
-783.4%
Q3 24
19.6%
-1404.0%
Q2 24
4.1%
EPS (diluted)
CTO
CTO
IBRX
IBRX
Q1 26
$0.13
Q4 25
$0.81
$-0.06
Q3 25
$0.03
$-0.07
Q2 25
$-0.77
$-0.10
Q1 25
$0.01
$-0.15
Q4 24
$-0.69
$-0.08
Q3 24
$0.17
$-0.14
Q2 24
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTO
CTO
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$8.3M
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$575.4M
$-500.5M
Total Assets
$1.3B
$501.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTO
CTO
IBRX
IBRX
Q1 26
$8.3M
Q4 25
$6.5M
$242.8M
Q3 25
$9.3M
$257.8M
Q2 25
$8.6M
$153.7M
Q1 25
$8.4M
$61.6M
Q4 24
$9.0M
$149.8M
Q3 24
$8.2M
$130.4M
Q2 24
$4.8M
Total Debt
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
$616.3M
Q3 25
$604.2M
Q2 25
$605.4M
Q1 25
$602.2M
Q4 24
$519.0M
Q3 24
$526.8M
Q2 24
$482.7M
Stockholders' Equity
CTO
CTO
IBRX
IBRX
Q1 26
$575.4M
Q4 25
$567.3M
$-500.5M
Q3 25
$557.3M
$-524.3M
Q2 25
$574.1M
$-570.7M
Q1 25
$593.9M
$-591.4M
Q4 24
$612.8M
$-489.1M
Q3 24
$595.8M
$-745.1M
Q2 24
$491.8M
Total Assets
CTO
CTO
IBRX
IBRX
Q1 26
$1.3B
Q4 25
$1.3B
$501.9M
Q3 25
$1.2B
$519.0M
Q2 25
$1.2B
$402.1M
Q1 25
$1.2B
$303.8M
Q4 24
$1.2B
$382.9M
Q3 24
$1.2B
$364.6M
Q2 24
$1.0B
Debt / Equity
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
1.09×
Q3 25
1.08×
Q2 25
1.05×
Q1 25
1.01×
Q4 24
0.85×
Q3 24
0.88×
Q2 24
0.98×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTO
CTO
IBRX
IBRX
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
$64.6M
$-70.4M
Q3 25
$25.5M
$-68.9M
Q2 25
$21.9M
$-79.7M
Q1 25
$10.3M
$-85.9M
Q4 24
$59.9M
$-85.1M
Q3 24
$21.2M
$-98.8M
Q2 24
$12.9M
Free Cash Flow
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
FCF Margin
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Capex Intensity
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Cash Conversion
CTO
CTO
IBRX
IBRX
Q1 26
Q4 25
2.28×
Q3 25
8.75×
Q2 25
Q1 25
4.56×
Q4 24
Q3 24
3.40×
Q2 24
10.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons